Healthcare / BiotechnologyUpdated 2026-05-10 22:07 UTC

NSE/CONCORDBIO stock hub

NSE/CONCORDBIO has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

NSE/CONCORDBIOis not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

122.8B

National Stock Exchange of India

Market data

Live price

Current market quote for this ticker.

Current price

NSE/CONCORDBIO

In the news

Latest news · NSE/CONCORDBIO

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/E33.3

P25 24.9P50 32.4P75 45.7

Trailing P/E39.5

P25 24.8P50 35.9P75 56.9

ROEn/a

P25 6.3P50 13.6P75 18.1

ROIC19

P25 4.1P50 10.3P75 17.9

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All NSE/CONCORDBIO market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

174

Groups with data

Currency

INR

Showing 174 of 174 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Country	India
Country code	IN
Employees	1,571
Employees Change	194%
Employees Change Percent	14.09
Enterprise value	INR 119.5B
Exchange	National Stock Exchange of India
Financial currency	INR
First seen	2026-05-10
Industry	Biotechnology
Isin	INE338H01029
Last refreshed	2026-05-10
Market cap	INR 122.8B
Price	INR 1,170
Price currency	INR
Rev Per Employee	7,375,524.51x
Sector	Healthcare
Sic	2834
Symbol	nse/CONCORDBIO
Website	https://www.concordbiotech.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	2.54%
EV Earnings	38.24x
EV/EBIT	31.5x
EV/EBITDA	27.51x
EV/Sales	10.31x
Forward P/E	33.32x
P/B ratio	6.72x
P/E ratio	39.54x
P/S ratio	10.6x
PE Ratio3 Y	52.65x
PEG ratio	2.41x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT Margin	32.61%
EBITDA Margin	37.2%
Gross margin	63.92%
Gross Profit	INR 7.4B
Gross Profit Growth	-7.99%
Gross Profit Growth Q	11.01%
Gross Profit Growth3 Y	11.03%
Net Income	INR 3.1B
Net Income Growth	-4.22%
Net Income Growth Q	-15.07%
Net Income Growth Years	3%
Net Income Growth3 Y	21.34%
Pretax Margin	35.74%
Profit Margin	26.97%
Profit Per Employee	INR 2M
Profitable Years	6
Roa5y	14.59
Roe5y	21.48
ROIC	18.97
Roic5y	23.6

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr1y	-15.7%
EPS Growth	-4.82
EPS Growth Q	-16.25
EPS Growth Years	3
EPS Growth3 Y	21.09
Revenue Growth	6.38x
Revenue Growth Q	13.74x
Revenue Growth Quarters	1x
Revenue Growth Years	5x
Revenue Growth3 Y	17.57x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Cash	INR 3.3B
Debt	INR 16.1M
Debt EBITDA	INR 0
Debt Equity	INR 0
Equity	INR 18.3B
Interest Coverage	1,282.3
Net Cash	INR 3.3B
Net Cash By Market Cap	INR 2.69
Net Cash Growth	17.64%
Net Debt EBITDA	INR -0.76
Net Debt Equity	INR -0.18
Tangible Book Value	INR 18.3B
Tangible Book Value Per Share	INR 173
WACC	7.78

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-0.63%
Dividend Growth	0%
Dividend Growth Years	2%
Dividend per share	INR 10.7
Dividend Years	2
Dividend Yield	0.91%
Last Dividend	INR 10.7
Payout Ratio	36.04%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
1Y total return	-15.69%
200-day SMA	1,397.2
50-day SMA	1,110.6
50-day SMA vs 200-day SMA	50under200
All Time High	2,664
All Time High Change	-56.08%
All Time High Date	2024-09-20
All Time Low	900.1
All Time Low Change	29.99%
All Time Low Date	2023-08-18
ATR	49.87
Beta	0.64
Beta1y	0.24
Beta2y	-0.03
Ch YTD	-13.05
High	1,202.4
High52	2,150.4
High52 Date	2025-06-11
High52ch	-45.59%
Low	1,168
Low52	987
Low52 Date	2026-04-02
Low52ch	18.54%
Ma50ch	5.35%
Price vs 200-day SMA	-16.26%
RSI	59.86
RSI Monthly	43.02
RSI Weekly	45.14
Sharpe ratio	-0.5x
Sortino ratio	-0.65
Total Return	0.28%
Tr YTD	-13.05
Tr1m	13.31%
Tr1w	-2.11%
Tr3m	-11.84%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Operating Income	INR 3.8B
Operating Income Growth	-6.81
Operating Income Growth Q	-5.26
Operating Income Growth3 Y	18.17
Operating margin	32.61

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	26,588,256%
Shares Insiders	60.9%
Shares Institutions	15.58%
Shares Out	104,616,204
Shares Qo Q	0.57%
Shares Yo Y	0.63%

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Average Volume	358,404.85x
Bv Per Share	173.3
Ch1m	13.31
Ch1w	-2.11
Ch1y	-16.23
Ch3m	-11.84
Ch6m	-16.12
Change	-2.39%
Change From Open	-2.35
Close	1,198.7
Days Gap	-0.05
Depreciation Amortization	531,747,250
Dollar Volume	182,293,020
Earnings Date	2026-05-15
EBIT	INR 3.8B
EBITDA	INR 4.3B
EPS	INR 29.69
F Score	1
Fiscal Year End	March
Founded	1,984
Graham Number	340.24217
Graham Upside	-70.92
Income Tax	INR 1B
Is Primary Listing	1
Last Earnings Date	2026-02-11
Last Report Date	2025-12-31
Lynch Fair Value	INR 633
Lynch Upside	-45.86
Ma150	1,292
Ma150ch	-9.44%
Ma20	1,096.5
Ma20ch	6.7%
Next Earnings Date	2026-05-15
Open	1,198.1
Payment Date	2025-10-09
Position In Range	5.81
Price Date	2026-05-08
Price EBITDA	INR 28.49
Ptbv Ratio	6.73
Relative Volume	0.43x
Revenue	11,586,949,000x
Tax By Revenue	8.89x
Tax Rate	24.86%
Tr6m	-16.12%
Volume	155,806

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

NSE/CONCORDBIO dividend yield, growth & safety

Yield, payout sustainability, and the multi-year growth streak.

Dividend yield

+0.9%

$10.7 annual per share

Payout ratio

+36.0%

Share of earnings returned as dividends. Below 60% is generally sustainable.

5Y dividend CAGR

n/a

2 consecutive years of growth

Total shareholder yield

+0.3%

Dividend yield + buyback yield combined

Performance

NSE/CONCORDBIO stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

Ownership

Who owns NSE/CONCORDBIO?

Insider, institutional, and short-interest positioning.

Institutional ownership

+15.6%

Share of float held by funds and institutions

Insider ownership

+60.9%

Stake held by company insiders. Higher generally signals alignment.

Short interest

n/a

Float sold short by bearish positioning

Y/Y dilution

+0.6%

Negative means the company is buying back shares.

Technical

NSE/CONCORDBIO momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

59.9

Neutral momentum band

Price vs 200-day MA

-16.3%

50/200-day relationship not available

Beta (5Y)

0.64

Less volatile than the market

Sharpe ratio

-0.50

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About NSE/CONCORDBIO

Hub-level FAQ points readers to the deeper analysis pages.

What is the current nse/CONCORDBIO stock rating?

nse/CONCORDBIO is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full nse/CONCORDBIO analysis?

The full report lives at /stocks/nse/CONCORDBIO/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for nse/CONCORDBIO?

The latest report frames nse/CONCORDBIO around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the nse/CONCORDBIO page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.